WHO Reference Reagent
Anti-HPA-15b (minimum potency)
NIBSC code: 18/220
Instructions for use
(Version 2.0, Dated 14/12/2020)

1. INTENDED USE
This preparation, when reconstituted and diluted as described below, should be used as a reference reagent for minimum acceptable potency for the detection of antibodies against Human Platelet Antigen-15b (HPA-15b). It should not be used for HPA-15b typing or any other purpose.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNTAGE
No units are assigned to this material.

4. CONTENTS
Country of origin of biological material: United Kingdom.
Each ampoule contains the residue after freeze-drying of 0.5 ml recalcified plasma. The plasma was collected from a single consenting donor. The immunoglobulin class of the anti-HPA-15b antibodies is IgG. Antibodies against other HPA antigens have not been detected in this preparation but antibodies against HLA Class 1 antigens are present, therefore this material should only be used in glycoprotein-specific assays (e.g. MAIPA). The HLA Class 1 antibody specificities detected are A2, A68, A69, C5, C8 and C15.

5. STORAGE
Store unopened ampoules at -20°C or below.
Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow instructions provided with the ampoule breaker.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution

Reconstitute the contents of one ampoule with 0.5 ml distilled water immediately before use, mix gently until fully reconstituted. Dilute immediately before use by adding 1 volume of reconstituted material to 7 volumes of diluent (e.g. Tris-buffered saline containing 0.2% (w/v) bovine serum albumin). Diluted material should then be tested for the presence of IgG anti-HPA-15b antibodies using HPA-15bb platelets or antigens in glycoprotein specific assays (i.e. MAIPA assays). This dilution (1 in 8) is the minimum dilution expected to give a positive result. However, many laboratories can detect anti-HPA-15b at larger dilutions of 18/220, as shown in the following histogram.

Data from collaborative study: titration of anti-HPA-15b in individual laboratories. Numbers in boxes indicate lab code number only.

8. STABILITY
Reference materials are held at NIBSC within assured temperature controlled facilities and they should be stored on receipt as indicated on the label. It is the policy of WHO not to assign an expiry date to their international reference materials.

Accelerated degradation studies have indicated that this material is suitably stable, when stored at -20°C or below, for the minimum potency value to remain valid until the material is withdrawn or replaced. The studies have shown that the material is suitably stable for shipment at ambient temperature without any effect on the minimum potency value.

At NIBSC, 18/220 once correctly reconstituted and stored between 4-8°C can be used in the CD109 MAIPA assay for up to 1 month without loss of activity. It is advised that laboratories carry out their own in-house stability studies to substantiate our findings.

Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

9. REFERENCES

10. ACKNOWLEDGEMENTS
We thank the participants of the collaborative study.

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards:
http://www.who.int/biologicals/en/
12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance: Pale yellow freeze-dried powder</td>
</tr>
<tr>
<td>Stable: Yes</td>
</tr>
<tr>
<td>Hygroscopic: No</td>
</tr>
<tr>
<td>Flammable: No</td>
</tr>
<tr>
<td>Other (specify): Contains material of human origin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Toxicological properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of inhalation: Not established, avoid inhalation</td>
</tr>
<tr>
<td>Effects of ingestion: Not established, avoid ingestion</td>
</tr>
<tr>
<td>Effects of skin absorption: Not established, avoid contact with skin</td>
</tr>
</tbody>
</table>

**Suggested First Aid**

- Inhalation: Seek medical advice
- Ingestion: Seek medical advice
- Contact with eyes: Wash with copious amounts of water. Seek medical advice
- Contact with skin: Wash thoroughly with water.

**Action on Spillage and Method of Disposal**

Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

- **Country of origin for customs purposes**: United Kingdom
- **Net weight**: 0.64g
- **Toxicity Statement**: Toxicity not assessed
- **Veterinary certificate or other statement if applicable**: Attached: No

17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biol_efstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.